1. Curriculum Vitae
Full first and surname (capital letters): Andriy Sapatyi
Professional phone number: +380637550557,+380669838448
Email Address: asapatyimed@gmail.com
Academic Qualification(s)
 M.D., PhD, Associate professor the chair of clinical pharmacologyand pharmacotherapy
Address
 Ivano-Frankivsk Regional Clinical Cardiological Center, Department of Arterial Hypertension, SHEI „Ivano-
Frankivsk National Medical University“, Chair of clinical pharmacology and pharmacotherapy, 114
H.Mazepy Str., Ivano-Frankivsk, 76018,Ukraine
Education and Training
Name and Location of Institution
(City, State or Province and Country) Degree and Year Awarded Area of Study
SHEI “Ivano-Frankivsk State Medical University”,
Ivano-Frankivsk, Ukraine
2004-2005 Internship - Internal
Medicine (Therapy)
SHEI “Ivano-Frankivsk State Medical University”,
Ivano-Frankivsk, Ukraine
SE “Institute of Pharmacology and Toxicology”,
Academy of Medical Sciences of Ukraine, Kyiv,
Ukraine
2005-2008 Postgraduate study for PhD
(Clinical pharmacology)
SHEI “Ivano-Frankivsk National Medical University”,
Ivano-Frankivsk, Ukraine
2004-2011 Assistant of the chair of
clinical pharmacology and
pharmacotherapy with
courses of bioethics and
biosafety
SHEI “Ivano-Frankivsk National Medical University”,
Ivano-Frankivsk, Ukraine
2011 – present time Associate professor (PhD)
of the chair of clinical
pharmacologyand
pharmacotherapy
Professional Experience
Position/Title
Name and Location of Institution
(City, State or Province and Country)
Dates
(Start/Stop Dates as
applicable)
Current
Associate professor (PhD) of the chair
of clinical pharmacology and
pharmacotherapy
SHEI „Ivano-Frankivsk National Medical
University“, Chair of clinical pharmacology
and pharmacotherapy, Ivano-Frankivsk,
Ukraine
2011 – presenttime
Current
Vice-dean of dean's office of the foreign
studentdepartment
SHEI „Ivano-Frankivsk National Medical
University“, Ivano-Frankivsk, Ukraine
2009 – presenttime
Previous
Assistant of the chair of clinical
pharmacology and pharmacotherapy
with courses ofbioethics and biosafety
SHEI „Ivano-Frankivsk National Medical
University“, Chair of clinical pharmacology
and pharmacotherapy with courses of
bioethics and biosafety
2004-2011
Previous participation in clinical trials
Indication of Trial
Clinical Phase
of Trial (I-IV) Role in Trial
Year in which
trial was
conducted
A phase 2, randomized, parallel group, multi-center,
multi-national study for the evaluation of safety of
four fixed dose regimens of oral anticoagulant drug
which acts as a direct factor Xa inhibitor in subjects
with non-valvular atrial fibrillation.
II Sub-Investigator
Study
Coordinator
2007-2008
A phase 3, Randomized, Double-Blind, Double-
Dummy, Parallel Group, Multi-Center, Multi-National
Study for Evaluation of Efficacy and Safety of
oral anticoagulant drug which acts as a direct factor
Xa inhibitor Versus a vitamin K antagonist in
Subjects with Atrial Fibrillation – Effective
Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation
III Sub-Investigator 2009-2013

2. Study assessing the morbidity-mortality benefits of
the If inhibitor in patients with coronary artery
disease
III Sub-Investigator 2011-2013
A Multi-Center, Prospective, Randomized, Double-
Blind, Placebo-Controlled, Parallel-Group Study to
Evaluate the Effect of omega-3-carboxylic acids on
Cardiovascular Health and Mortality in
Hypertriglyceridemic Patients with Cardiovascular
Disease or atHigh Risk for Cardiovascular Disease
III Sub-Investigator 2012-ongoing
Prospective, multicentre, international Registry of
male and female patients newly diagnosed with
atrial fibrillation
Prospective Sub-Investigator 2012-ongoing
Efficacy and safety of fixed-dose combination ACE
inhibitor 5 mg / thiazide-like diuretic 1.25 mg / Ca-
channels blocker 5 mg versus ACE inhibitor 5 mg /
thiazide-like diuretic 1.25 mg single pill in patients
with uncontrolled essential hypertension after 1
month of treatment by ACE inhibitor
5 mg / thiazide-like diuretic 1.25 mg single pill. An
international, multicentre, randomised, double blind,
12-weeks superioritystudy.
III Sub-Investigator 2013-2015
Training on ICH/GCP: YES If yes, specifybelow NO
 Introduction to the Clinical Drug Development Process: ICH Good Clinical Practice for Clinical Trial
Sites,February 8, 2016
Published works in foreign journals:
 Sapatyi Andriy, Kupnovytska I.G., Dzvinyatska O.F., Belegai R.I., Kutynska I.P. Prospects of research of
drugs with metabolic action in the treatment of the patients with heart’s diseases // 6th Global
CardioVascular Clinical Trialists Forum – Paris 2009,P.53
 Andriy Sapatyi, Iryna Kupnovytska New antioxidant properties of Corvitin in the treatment of patients with
acute myocardial infarction and chronic heart failure // 9th
Global Cardiovascular Clinical Trialists Foum – 30
Nov 2012 – 01 Dec 2012,Paris
 A. Sapatyi, І.G. Kupnovytska, R.I. Belegai Evaluation of endothelial dysfunction in patients with arterial
hypertension and chronic heartfailure // Heart failure,May 2014, ESC, P.871
 A. Sapatyi, І.G. Kupnovytska, R.I. Belegai Evaluation of quality of life of patients with acute myocardial
infarction, developed and ran on the background of arterial hypertension and chronic heart failure // Heart
failure,May 2014, ESC, P.872
 A. Sapatyi, R. Belegai, L. Kovalchuk Corrective action of soluble Quercetin on cardiac arrhythmias induced
by peroxynitrite in vitro // 2nd World Congress on Acute Heart Failure as a main part of the congress.
Seviile, Spain,23-26 May 2015. P1067
 A. Sapatyi, R. Belegai, I. Kupnovytska, L. Kovalchuk Prevention of arrhythmias in patients with acute
myocardial infarction during treatment with bioflavonoids // 2nd World Congress on Acute Heart Failure as a
main partof the congress. Seviile, Spain,23-26 May 2015.P277
Date: _____________________
Signature__________________ Andriy Sapatyi